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SUMMARY 
To adopt an efficient approach of identifying rare variants possibly related to Hirschsprung disease 
(HSCR), a pilot study was set up to evaluate the performance of a newly designed protocol for next 
generation targeted resquencing. In total 20 Chinese HSCR patients and 20 Chinese sexmatched 
individuals with no HSCR were included, for which coding sequences (CDS) of 62 genes known to 
be in signaling pathways relevant to enteric nervous system (ENS) development were selected for 
capture and sequencing. Blood DNAs from eight pools of five cases or controls were enriched by 
PCR-basedRaindance technology (RDT) and then sequenced on a 454 FLX platform. As technical 
validation, five patients from case Pool-3 were also independently enriched by RDT, indexed with 
barcode and sequenced with sufficient coverage. Assessment for CDS single nucleotide variants 
showed DNA pooling performed well (specificity/sensitivity at98.4%/83.7%) at the common variant 
level; but relatively worse (specificity/sensitivity at 65.5%/61.3%) at the rare variant level. Further 
Sanger sequencing only validated five out of 12 rare damaging variants likely involved in HSCR. 
Hence more improvement at variant detection and sequencing technology is needed to realize the 
potential of DNA pooling for large-scale resequencing projects. 
Keywords: HSCR; targeted resequencing; CDS; rare variant; Raindance 
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INTRODUCTION 
Targeted resequencing is a direct approach to pinpoint the causal or associated rare 
variants/mutations (RVs) in one or a few given genes (Rehm, 2013). The combination of PCR-based 
enrichment (for targeted sequence regions) and first-generation sequencing platforms (Sanger 
sequencing on ABI 3730 sequencer) is very efficient and is considered as the gold standard method 
for validating DNA mutations. However, due to the high cost, large-scale Sanger sequencing is not 
applicable to the screening of patients affected by multi-genic diseases where the number of 
candidate genes to be screened for RVs may easily be larger than 10.Next generation sequencing and 
microarray-based enrichment technologies (multiplex capture)offer not only high coverage of 
sequence reads, but also good capture specificity for targeted DNA regions withinaffordable research 
budgets(Summerer et al., 2009). This combination, next generation targeted resequencing, has been 
adopted for clinical genetic testing ofhereditary cancers, cardiac diseases and sensory disorders 
where the genetic mechanisms are relatively well understood(Rehm, 2013). Meanwhile, it also 
enables population-based research that aims to further explore the roles of RVs in a batch of candidate 
genes identified by previous linkage or association studies.  
Hirschsprung disease (HSCR, aganglionicmegacolon) is a complex genetic disorder of the 
enteric nervous system (ENS) characterized by the absence of enteric neurons along a variable length 
of the intestine. This is attributed to a failure in the migration of the enteric neuronprecursors, the 
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neural crest cells (NCCs) (Torfs, 2004, Amiel et al., 2008). The receptor tyrosine kinase gene (RET) 
is the major HSCR gene and its expression is crucial for the development of the enteric ganglia and 
hence the ENS (Amiel & Lyonnet, 2001). RVs in the coding sequence (CDS) of RET account for up to 
50% of the familial cases and between 10%-20% of the sporadic cases. In addition to CDS mutations, 
RET common variants (single nucleotide polymorphisms -SNPs) are strongly associated with HSCR 
(Emison et al., 2005). Yet, despite the importance of RET, additional genes (acting either in 
conjunction or independently from RET) are necessary to explain not only the disease incidence but 
also its complex pattern of inheritance. Other HSCR genes identified so far mainly code for protein 
members of inter-related signaling pathways involved in the ENS development: endothelin receptor 
B (EDNRB), the transcriptional regulator SOX10and the NRG1/ERBB2signaling pathway 
gene(Hofstra et al., 1999, Heanue & Pachnis, 2007, Garcia-Barcelo et al., 2009).CDS mutations in 
genes other than RET thus far only account for 7% of the cases, however the unexplained phenotypic 
variance in sporadic HSCR cases is still very high (>80%)(Gui et al., 2013).This suggests that 
variations in other genes involved in ENS development are likely to contribute to the manifestation of 
the phenotype (Heanue & Pachnis, 2007). Nevertheless, not many of the known or candidate genes 
have been systematically screened in HSCR patients aside from RET.  Hence it is promising to adopt 
multiplex capture and parallel sequencing to efficiently identify rare variants residing in 
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genemembers of these signaling pathways relevant to processes that, when altered, give rise to 
diseases. 
Targeted sequencing on complex diseases has previously shown that a population-based 
design involving > 1000 cases/controls is always required (Wu et al., 2011). However, a few technical 
issues need to be handled before this large-scale sequencing project proceeds on HSCR. This includes 
selection of candidate genes, design of capture kits, and choice of multiplexing sequencing, among 
others (Mertes et al., 2011). Therefore, we set up a pilot study in which a new strategy of NGS-based 
target resequencing was conducted on a relatively small sample of HSCR patients and normal 
controls. Evaluation of this strategy would provide technical guidance on future targeted 
resequencing studies on complex diseases including HSCR. 
 
MATERIALS AND METHODS 
Sample collection 
HSCR diagnosis was based on histological examination of either biopsy or surgical resection 
material for absence of enteric plexuses. Patients were also fully characterized and a 
pro-formaquestionarewas provided for each patient. In total 20 HSCR patients (16 males and 
fourfemales) were included in this pilot study. As controls, we included 20 Chinese individuals (16 
males and four females) with no HSCR. Adult individuals gave written informed consent and for 
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minors, written informed consent was obtained from their parents. The study was approved by the 
institutional review board of The University of Hong Kong together with the Hospital Authority 
(IRB:UW09-360). 
 
Gene selection 
Candidate genes were selected according to the evidence oftheir involvement in ENS 
development (provided by either the phenotype presented by mouse models, in vitro data,orin silico 
data). All of the14 genes known to cause HSCR in human newborns and ENS failure in the 
embryonic mouse (Table 1) werecompulsorily included, while the other 48 genes (Table S1) were 
selected according to the following reasons: 1) key members in the same signaling pathway with 
know HSCR genes; 2) genes with suggestive association with HSCR in our previous GWAS study 
(Garcia-Barcelo et al., 2009); 3) supported by murineor functional studies as outlinedin Table S1. 
 
DNA pooling 
To minimize the cost, a protocol of DNA pooling that was previously recommended in 
large-scale genotyping studies was adopted (Sham et al., 2002). In detail, DNA wasextracted 
fromperipheral blood samples (20 cases and 20 controls) and was fragmented into 2~4Kb fragments 
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by sonication. DNA concentrations were measured by picogreen reagent in triplicate and were 
normalized to 10ng/μl.These genomic DNA samples were then arranged into pools with five cases or 
controls each in order to maximize the usage of the multiplex design, given the length of gene locus 
and PCR amplification. In overall, eight DNA templates (pool of DNA from five individuals and PCR 
reagents) were prepared, 
 
Enrichment and capture 
RainDance Technology (RDT 1000; RainDance Technologies, Lexington, MA, USA) was 
chosen to conduct multiplex capture for targeted regions (all exons + 2kb of 5’ and 3’ flanking UTR) 
ofthe 62 candidate genes. Basically, RDT allows us to PCR-amplify up to 4000 selected 500bp length 
sequences per DNA template by providing a custom-made pooled primer-pair library 
(http://www.raindancetechnologies.com). In brief, aliquoted primers were loaded on the RDT 1000 
enrichment chip along with a conventional PCR mix and 3-4μg of fractionated (to facilitate primer 
annealing) pooled-genomic DNA. During this process, each primer pair droplet merged with a 
droplet that contained genomic DNA, and PCR reagents. Approximately 1.5 million droplets were 
collected in a 0.2mL single tube and were directly PCR amplified. Amplification products were 
recovered by breaking the emulsion followed by purification using a MiniElute PCR Purification Kit 
(QIAGEN, QIAGEN Hong Kong Pte. Limited, Hong Kong).The whole strategy isshown in Figure 
Targeted resequencingand DNA pooling 
9 
 
S1. 
 
Sequencing 
During preparation of the sequencing library, purified PCR products generated in the previous 
steps were ligated to two distinct oligonucleotide adapters to provide priming sites for subsequent 
amplification and sequencing (Shendure & Ji, 2008, Rothberg & Leamon, 2008).The templates were 
amplified and immobilized by compartmentalizing individual template molecules and 28-m DNA 
capture beads within droplets of an emulsion. PCR reactions conducted inside the droplets amplified 
the template molecules and complementary primers covalently attached to the DNA capture beads 
immobilizedthe template. Template-covered DNA capture beads were loaded into individual wells 
etched into the surface of a fiber-optic slide.The sequencing process is the same as that used in 
pyrosequencing (454 Genome Sequencer FLX, Roche Inc., Branford, USA). Raw sequence reads 
were handled by the GS Data Analysis Software package accompanied by the GSFLXsystem, using 
gsMapper for alignment (human reference genome 19) and Newbler for variant calling (Roche Inc.). 
Only those single nucleotide variants (SNVs) with relatively high quality annotations (total read 
depth > 40, alternative allele > 3, and phred score > 20) were included for downstream analysis. 
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Technical validation 
To evaluate the proposed protocol at detecting true single nucleotide variants, one pool of 
samples (five HSCR patients in case pool-3) was individually sequenced with high coverage 
(>300×).This pool was selected since all those five patients were also genotyped by Affymetrix 
500K in our previous genome-wide association study (Garcia-Barcelo et al., 2009). The same 
RainDancetechnology was used to capture and enrich coding sequences of 62 candidate genes; 
however, DNA template was prepared using independent index primersfor each individual without 
pooling and was then sequenced on an IlluminaGAIIX platform (Illumina, San Diego,USA). Raw 
reads in fastq format were exported and aligned to human reference genome build 19 with BWA 
software (Li & Homer, 2010). The GATK pipeline was then used to preprocess each sequence 
(re-alignment, recalibration) and to call SNVs on multiple samples together (DePristo et al., 
2011).Only SNVs with total read depth > 8, allelic ratio for alternative allele > 0.25, and Phred 
score > 20) were reported. 
 
Variant assessment 
All genetic variants were annotated by KGGSeq and then classified into noncoding or coding 
(defined by Refgene), common or rare (minor allele frequency < 0.01 in dbSNP137), and damaging 
or non-damaging by Polyphen2(Li et al., 2012). Rare damaging variants detected in pool-3 patients 
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were validated by Sanger sequencing. The sensitivity and specificity of detecting two types of 
variants (common and rare) by DNA pooling were calculated from the overlapped or 
non-overlapped counts between variants found in one sequenced pool and variants found in all 
individually sequenced patients. 
 
Rare variant prioritization 
In order to pinpoint the most deleterious mutations that separate cases from controls, a 
step-by-step filtering was conducted on all variants found in different pools according to 
MAFreported in public databases (1000 Genomes Project, dbSNP137 and NHLBI Exome 
sequencing project), their functional impact and variant/gene recurrence across pools. Burden 
analysis (binomial test for the variant count difference between cases and controls) was performed 
on variants or genes retained at each level(Zhao et al., 2012). A final set of rare damaging variants 
from genes present in case pools only were sent for validation using Sanger sequencing.  
 
RESULTS 
Coverage (average read depth per base on targeted regions) and target specificity (unique reads 
on targets over total unique reads) were used to evaluate read-level performance. As shown in Table 
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2, the average read depth across the target regions for RDT was above 80×across eight pools, with 
range from 54.21× to 93.53×. In addition, the target specificity was 74.18% forRDT, while 74.12% 
of the RDT targeted bases were covered with depth >=40. In terms of variant calling, our protocol 
detected 943 raw SNVs (149 within CDS, 13.6%) per pool. Only those SNVs located in CDS 
regions were assessed. In overall, 89.5% CDS SNVs were also found in dbSNP137 (Table 2). 
Variants detected in the pool-3 sample were compared between pooled sequencing and 
individual indexed sequencing on the same five cases. The validity of using individual sequence as 
technical validation was indicated by their read depth coverage (>300×), dbSNP137 coverage 
(~92%) and concordance with GWAS array (>95%) (Table 3). In general, the specificity and 
sensitivity for pooled sequencing were 92% (139 out of 151) and 79.4%(139 out of 175) 
respectively. When classified into common or rare variants according to dbSNP137 (MAF at 0.01), 
the specificity and sensitivity were98.4%/83.3.7%, or 65.5%/61.3% respectively (Table 4). This 
difference was verified by using small set common variants overlapped with the SNP array, and rare 
damaging variants validated by Sanger sequencing. By pooled sequencing, 11 out of 13 SNPs were 
found and all of them matched the minor/major allele by counting sequence reads covering 
reference or alternative alleles. On the other hand, six out of 10 rare damaging variants found by 
pooled sequencing were verified by Sanger, compared to seven out of eight variants for individual 
sequencing. 
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Among all eight pools, 366 coding sequence SNVsin20 different HSCR cases and 20 healthy 
controls were detected by our protocol. The distribution of variant count in cases and controls is 
shown in Table 5, as stratified by allele frequency and deleteriousness. No significant burden was 
found for mutation load at any level between cases and controls (p-value >0.05; Table 5). With 
regard to genes carrying rare damaging mutations, thesecould be classified into case-only, 
case-control and control-only by the presence of at least one mutation. None of these, however,were 
shown to have a significant burden in HSCR cases versus healthy controls(data not shown). 
Nevertheless, genes uniquely mutated in patients only may be considered as functional hits for 
further analysis. Therefore 12SNVscontained in these genes were selected for validation by Sanger 
sequencing. Finally,fiveout of these 12 variants were successfully validated (data not shown);at the 
phenotype level, only fourout of 20 patients (oneshort male, oneshort female and twolong female 
cases; 20%) carried at least one validated mutation with high functional impact. 
DISCUSSION 
In our current study,we designed a protocol combining DNA pooling, RDT multiplex capture and 
next generation sequencing together for targeted resequencing research. Its performance was 
carefully evaluated through the application on an HSCR case/control dataset. The idea of DNA 
pooling was widely applied for studying disease risk variants in large-scale population samples(Sham 
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et al., 2002). An efficient association can be done by comparing minor allele frequency between case 
pools and control pools, without knowing the exact individual genotype. This was supported by our 
pooled sequencing for common variants, for whichthe presence of a variant can be detected by 
counting reads harboring reference alleles and alternative alleles.However, this approach did not 
seem reasonable when examining rare variants, as revealed by the high false positive rate and high 
false negative rate found in our study. 
It is true that barcoding individual samples in targeted sequencing would be a better approach 
for detecting rare variants (Cummings et al., 2010). However, it will be much more laborious and 
expensive than DNA pooling in a large-scale population-based study. From the perspective of other 
technologies besides DNA pooling in our protocol, on-target reads showed capture specificity for 
RDT was relatively better than hybridization-based capture on the same 62 candidate genes (our 
own published data, the Centre for Genomic Sciences, the University of Hong Kong), which may 
be ascribed to its higher specificity for pseudo-genes (including other paralogous sequences) and 
total targeted regions < 1M base pairs(Mondal et al., 2011). Given the advantage of multiplex capture 
technology been considered, the current drawback could be overcome by improving the performance 
of the NGS sequencer in terms of read accuracy together with cost-efficiency.  It is sensible to 
envisage the potential of DNA pooling as sequencing technology advances. 
Because of the intricate ways in which biological processes operate, rare (especially damaging) 
Targeted resequencingand DNA pooling 
15 
 
variants are likely to differ among individuals with the same disease, thus accounting for 
phenotypic variability. Of note is the fact that RVs identified in HSCR patients happen to belong to 
pathways involved in ENS development (Heanue & Pachnis, 2007, Heanue & Pachnis, 2006). 
However, we were not able to prioritize genes by binomial tests mainly because of limited power 
given the small sample size, low frequency of effective variants and relatively low specificity and 
sensitivity of the technologies (Kiezun et al., 2012). A simplified estimation on variant level 
indicated that 600 case-control pairs is needed to detect RVs with odds ratio (OR) above 2 and 
minor allele frequency above 1% (supplementary Figure 2). To boost power of detecting more rare 
variants with moderate effect size (OR <2), gene-wise burden tests should be adopted (Bansal et al., 
2010). 
While it is true that RVs need not always be in CDSs and that RVs may include short 
insertion/deletions (Indels) and longer structural variations (copy number variations, translocations), 
further investigation on other types of rare variants in candidate genes and whole genomic regions 
(exome sequencing or whole genome sequencing)are necessary to better explain our HSCR patients 
not carrying rare damaging SNVs. Full genomic profiles would also give an opportunity to later risk 
prediction that integrate both common risk variants (RET and NRG1) and rare risk mutations. In 
addition, replication is always needed since the involvement of a mutated gene/chromosomal region 
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in the disease may only be consolidated by the identification of recurrent mutations or genes in an 
independent group of patients(Veltman & Brunner, 2012, Gilissen et al., 2012, Vissers et al., 2010). 
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TABLES 
Table 1:  Genes reported to cause HSCR when mutated 
Genes Type of gene Chr Length1 Exons Transcript1 Human+ Mouse∫ Frequency* 
RET Cell surface receptor 10q11 53,283 21 5,611  HSCR Absence EN 50% F/7-35%S 
GDNF Neurotrophic factor 5p13 27,004 3 3,752 HSCR Absence EN Very rare 
GFRA1 Cell surface receptor 10q25 210,024 10 1,539 HSCR Absence EN 1 patient 
NRTN Neuronal growth factor 19p13 4,518 2 1,103 HSCR Abnormal ENS Very rare 
PHOX2B Transcription factor 4p13 4,888 3 3,029 Haddad Syndrome0 Abnormal ENS - 
NKX2.1 Transcription factor 14q13 3,815 3 2,165 HSCR ND Very rare 
SOX10 Transcription factor 22q13 15,123 4 2,861 WS40 Absence EN - 
NRG1 Signaling protein 8p12 1,124,806 17 3,000 HSCR Abnormal NCC migration - 
EDNRB Transmembrane receptor 13q22 80,049 8 4,310 HSCR/WS40 Absence EN 3-7% 
EDN3 Vasoactive peptide 20q13 25,566 6 2,397 WS40 Absence EN <5% 
Targeted resequencingand DNA pooling 
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ECE-1 Enzyme 1p36 126,921 19 2,764 HSCR Absence EN Very rare 
KIAA1279 Binding protein 10q21 28,246 7 2,524 GSM syndrome0 ND - 
ZFXH1B Binding protein 2q22 132,334 10 5,558 MW syndrome0 Abnormal NCC migration - 
L1CAM Cell adhension molecules Xq28 24,630 29 5,113 Hydrocephalus/HSCR# Delayed NCC 
differentiation# 
- 
TOTAL   142 45,726    
1:  in base pairs.  EN: entericneurons.ENS: enteric nervous system.  NCC: neural crest cell.  +:when not specified, isolated (non-syndromic) 
HSCR.  ∫: Mouse Genome Informatics search tool; phenotype refers only to gut/ENS system.  *: % of isolated HSCR patients with coding region 
mutations in these genes, data from (Heanue & Pachnis, 2007, Amiel & Lyonnet, 2001, Doray et al., 1998).  -: no patients with isolated HSCR 
reported. #: Referred from Human disease model (Griseri et al., 2009) or mouse model (Turner et al., 2009). F= familial.  S= sporadic.  0: HSCR 
is part of the syndrome.WS4: Waardenburg-Shah type 4 syndrome.  GSM: Goldberg-ShprintzenMegacolon.  MW:Mowat-Wilson.  ND:  no 
abnormal gut phenotype described. 
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Table 2 Quality summary of sequencing and SNV calling per sample pool 
 
  Sample 
Group* 
Unique Reads on 
Targets# 
Target specificity (%) $ Mean Coverage 
Target Regions with 
depth ≥ 40 (%) 
Raw SNVs CDS CNVs 
dbSNP137 
coverage (%) 
HS1 235,854 68.58 71 67.17 1015 131 88.55 
HS2 320,415 74.63 99 81.93 1407 181 82.32 
HS3 276,321 76.00 90 78.75 1200 151 90.07 
HS4 263,895 74.12 85 72.35 1121 153 92.16 
HS5 276,517 72.59 90 72.87 1131 153 90.2 
HS6 296,667 69.76 91 72.13 1140 162 85.19 
HS7 229,107 77.81 61 54.21 811 109 95.41 
HS8 271,618 79.93 76 93.53 910 131 92.37 
Mean 271,299 74.18 83 74.12 1092 149 89.53 
*, Each sample pool (HS1-4 for cases only, HS5-8 for controls only) contains fiveindependent samples.$, target specificity was measured as unique reads on targets over total 
unique reads  
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Table 3 Quality summary for individual sequencing of Pool-3 samples 
SampleID 
Targeted 
Read Count 
Average 
Read depth 
RawSNVs* CDS SNVs* 
dbSNP137coverage 
(%) 
GWAS 
concordance (%)# 
HK109C 10,455,485 304.1× 876 93 92.39 95.40 
HK113C 12,892,678 379.3× 967 96 95.83 96.60 
HK119C 14,576,191 430.6× 958 92 93.41 97.70 
HK128C 13,142,489 386.7× 970 93 96.77 95.40 
HK138C 12,671,332 372.1× 941 112 94.64 93.00 
Mean 13,653,900 374.6× 942 97 94.61 95.60 
*, there were 1605 raw SNVs (including 175 CDS SNVs) that are unique from all fiveindividuals. #, 87 SNVs (covered by both GWAS arrays and targeted 
resequencing) were used to estimate the genotype concordance.Genotype concordance was calculated as the total number of matching genotypes out of all valid 
comparisons for which the same variants (position and reference/alternative allele) were genotyped bybothGWAS arrays and resequencing. 
 24 
 
Table 4 Comparison of CDS SNVs detected by individual sequencing and pooled 
sequencing on Pool-3 patients 
Technology All Common 
SNP 
array 
Rare 
Rare 
damaging 
(Sanger) 
Individual 
sequencing 
175 144 13 31 8 (7) 
Pooled sequencing 151 122 11 29 10 (6) 
Overlapped 139 120 11$ 19 6 (6) 
$ individual genotype was not available, concordant variants were roughly estimated by comparing the 
consistency of major allele and minor allele. 
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Table 5 Summary of variants from all eight pools forHSCR cases and healthy 
controls 
Variant set Total Case Control 
P-value 
(burden test) 
All variant 366 284 246 NA 
Rare variants (RVs) 166 99 74 0.265 1 
Rare damaging variants 
(RDVs) 
35 16 19 0.131 2 
RDVs present in 
Case-unique genes 
(Sanger validated) 
12 (5) 12 (5) NA NA 
1 burden test for overall count of rare variants among all variant; 2 burden test for overall count of RDVs 
among RVs; NA means not available  
 
 
